2021 ASH Annual Meeting: Focus on CAR-T
The chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (liso-cel) significantly improved event-free ...
According to results from the phase III BELINDA trial, patients with relapsed/refractory aggressive B-cell non-Hodgkin ...
The chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel) demonstrated significant and ...
First-line treatment with the autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy axicabtagene ...
In a single-arm phase I/II study, infusion with CT103A, a novel fully human B-cell maturation antigen (BCMA)-targeted ...
Chimeric antigen receptor (CAR) T-cell therapy is a potentially life-saving option for patients with hematologic ...
According to results from the phase III BELINDA trial, patients with relapsed/refractory aggressive B-cell non-Hodgkin ...
Black Americans were severely under-represented in clinical trials that supported FDA approvals of chimeric antigen ...
Findings from phase II of the phase I/II MajesTEC-1 study on teclistamab were presented for the first time at the 2021 ...
A study reported updated results from the CARTITUDE-1 trial, which previously showed that cilacabtagene autoleucel ...
Prescribing chemotherapy is not a universal practice of advanced practice providers (APPs) in the oncology community, ...
According to new research presented during the 2021 ASH Annual Meeting, circulating tumor DNA (ctDNA) accurately ...
Chimeric antigen receptor (CAR) T-cell therapy with lisocabtagene maraleucel (liso-cel) significantly improved ...
Peripheral blood cytopenia is a persistent clinical challenge and, according to findings from the REGARDS trial, it may ...
Despite advances in novel therapies, survival rates remain poor for patients with relapsed/refractory aggressive B-cell ...
In a phase I trial, the B-cell maturation antigen (BCMA)–targeting chimeric antigen receptor (CAR) T-cell therapy ...
According to data from the ZUMA-7 trial, the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel ...
A recent study of KTE-X19 (also known as brexucabtagene autoleucel) supports the use of chimeric antigen receptor (CAR) ...
Advertisement
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.